BiomX Inc. (PHGE) Discontinues Phase 2b Study, Initiates Insolvency Proceedings for Subsidiary
BiomX Inc. (PHGE) discontinued its Phase 2b study and initiated insolvency proceedings for subsidiary BiomX Ltd. on December 11, 2025.
Teva Pharmaceutical (TEVA) Amends Credit Facility, Extends Maturity to 2028
Teva Pharmaceutical (TEVA) amended its revolving credit agreement, extending the maturity date to April 29, 2028, and adjusting financial covenants.
MAIA Biotechnology (MAIA) Initiates Phase 3 Trial for Ateganosine in NSCLC, Receives FDA Fast Track Designation
MAIA Biotechnology (MAIA) filed an 8-K on Dec 11, 2025, disclosing Phase 3 trial initiation and FDA Fast Track designation for Ateganosine in NSCLC.
Tenaya Therapeutics (TNYA) Reports Positive Interim Data for Gene Therapy TN-401 in ARVC Trial
Tenaya Therapeutics (TNYA) disclosed positive interim Phase 1b/2 data for TN-401 in PKP2-associated ARVC, showing increased protein expression and reduced arrhythmias.
Cadrenal Therapeutics (CVKD) Acquires VLX-1005 for HIT Treatment in $200,000 Deal
Cadrenal Therapeutics (CVKD) acquired VLX-1005 for Heparin-Induced Thrombocytopenia treatment in a $200,000 asset purchase.